Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;56(6):870-9.
doi: 10.1093/cid/cis919. Epub 2012 Oct 22.

Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study

Helen Kovari  1 , Caroline A Sabin, Bruno Ledergerber, Lene Ryom, Signe W Worm, Colette Smith, Andrew Phillips, Peter Reiss, Eric Fontas, Kathy Petoumenos, Stéphane De Wit, Philippe Morlat, Jens D Lundgren, Rainer Weber
Affiliations

Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study

Helen Kovari et al. Clin Infect Dis. 2013 Mar.

Abstract

Background: Liver diseases are the leading causes of death in human immunodeficiency virus (HIV)-positive persons since the widespread use of combination antiretroviral treatment (cART). Most of these deaths are due to hepatitis C (HCV) or B (HBV) virus coinfections. Little is known about other causes. Prolonged exposure to some antiretroviral drugs might increase hepatic mortality.

Methods: All patients in the Data Collection on Adverse Events of Anti-HIV Drugs study without HCV or HBV coinfection were prospectively followed from date of entry until death or last follow-up. In patients with liver-related death, clinical charts were reviewed using a structured questionnaire.

Results: We followed 22 910 participants without hepatitis virus coinfection for 114 478 person-years. There were 12 liver-related deaths (incidence, 0.10/1000 person-years); 7 due to severe alcohol use and 5 due to established ART-related toxicity. The rate of ART-related deaths in treatment-experienced persons was 0.04/1000 person-years (95% confidence interval, .01, .10).

Conclusions: We found a low incidence of liver-related deaths in HIV-infected persons without HCV or HBV coinfection. Liver-related mortality because of ART-related toxicity was rare.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient flowchart. Abbreviations: D:A:D, Data Collection on Adverse Events of Anti-HIV Drug; HBV, hepatitis B virus; HCV, hepatitis C virus.
See this image and copyright information in PMC

References

    1. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–41. - PubMed
    1. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The “Mortalite 2000 and 2005” surveys (ANRS EN19 and Mortavic) J Acquir Immune Defic Syndr. 2008;48:590–8. - PubMed
    1. Rosenthal E, Salmon-Ceron D, Lewden C, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19) HIV Med. 2009;10:282–9. - PubMed
    1. Smith C. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24:1537–48. - PubMed
    1. Kovari H, Weber R. Influence of antiretroviral therapy on liver disease. Curr Opin HIV AIDS. 2011;6:272–7. - PubMed

Publication types

MeSH terms

Substances